---
title: "Bioline RX：2025 全年業績"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280217686.md"
description: "BioLineRx Ltd.（納斯達克代碼：BLRX）公佈了其 2025 財務業績，顯示許可收入為 120 萬美元，淨運營虧損為 1030 萬美元。該公司宣佈與 Hemispherian 的合資企業 Tetragon Biosciences 計劃在 2026 年 3 月底之前開始對膠質母細胞瘤患者進行篩查"
datetime: "2026-03-23T21:27:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280217686.md)
  - [en](https://longbridge.com/en/news/280217686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280217686.md)
---

# Bioline RX：2025 全年業績

By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported 2025 financial and operational results in a March 23rd, 2026, press release. For the year, it produced license revenues of $1.2 million and a net operating loss of $10.3 million. The joint venture (JV) with Hemispherian, called Tetragon Biosciences, expects to begin screening patients by the end of this month for the glioblastoma...

### 相關股票

- [BLRX.US](https://longbridge.com/zh-HK/quote/BLRX.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)

## 相關資訊與研究

- [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md)
- [Bioline RX 啓動 GLIX1 在複發性膠質母細胞瘤中的 1/2a 期臨牀試驗](https://longbridge.com/zh-HK/news/286900261.md)
- [SpaceX 選擇納斯達克作為其 IPO 的上市場所](https://longbridge.com/zh-HK/news/286604046.md)
- [MetaOptics - 擬納斯達克雙重上市最新進展](https://longbridge.com/zh-HK/news/285138867.md)
- [定義 “醫院 AI 操作系統”：北協和、南湘雅等頂級醫院 為何集體選擇醫渡科技？](https://longbridge.com/zh-HK/news/286870257.md)